In addition, targeting DNL by suppression of citrate transport pathways will be one of the therapeutic interventions of metabolic disorders resulting from the synthesis of excess lipids in human obesity, hyperlipidemia, hyper‐cholesterolemia, and type 2 diabetes. Here, DNASE2 is linked to metabolic disease.